首页> 外文OA文献 >Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

【2h】

Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

机译：血清淀粉样蛋白A作为受前表达PD-L1影响的患者患者Pembrolizumab疗效的潜在生物标志物：探索性“预测”研究的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Vincenzo Di Noia; Ettore D’Argento; Sara Pilotto; Emanuele Vita; Miriam Grazia Ferrara; Paola Damiano; Marta Ribelli; Antonella Cannella; Antonella Virtuoso; Andrea Fattorossi; Giovanni Luca Ceresoli; Michele Milella; Giordano Domenico Beretta; Giampaolo Tortora; Emilio Bria;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study [J] . Di Noia Vincenzo, DArgento Ettore, Pilotto Sara, Cancer immunology, immunotherapy : . 2021,第6期

机译：血清淀粉样蛋白A作为受前抑制PD-L1影响的患者Pembrolizumab疗效的潜在生物标志物PD-L1：探索性“预测”研究的结果
2. 83?The prognostic significance of peripheral blood biomarkers in patients with advanced non-small cell lung cancer treated with pembrolizumab: a clinical study [J] . Kira MacDougall, Muhammad Niazi, Jeff Hosry, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：83？用Pembolizumab治疗的晚期非小细胞肺癌患者外周血生物标志物的预后意义：临床研究
3. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001) [J] . Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya, Investigational new drugs. . 2019,第6期

机译：Pembrolizumab作为先进非小细胞肺癌的一线治疗的疗效和安全性，具有至少50％PD-L1积极性：多中心回顾性队列研究（Hope-001）
4. Radiomics Biomarkers from PET/CT Multi-modality Fusion Images for the Prediction of Immunotherapy Response in Advanced Non-small Cell Lung Cancer Patients [C] . Wei Mu, Jin Qi, Hong Lu, SPIE Medical Imaging Conference . 2018

机译：PET / CT多模态融合图像的放射性标记生物标志物用于预测晚期非小细胞肺癌患者的免疫治疗反应
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study [O] . Saeka Egami, Hitoshi Kawazoe, Hironobu Hashimoto, 2021

机译：外周血生物标志物预测用Pembrozumab治疗的非小细胞肺癌患者免疫相关不良事件：多中心回顾性研究
7. P1.01-69 Blood Serum Amyloid A as Potential Predictor of Response to First-Line Pembrolizumab in Patients with Advanced Non-Small-Cell Lung Cancer [O] . V. Di Noia, C. Carbone, E. Vita, 2019

机译：P1.01-69血液血清淀粉样蛋白A作为对先进的非小细胞肺癌患者对第一线PEMBROLIZUAB的潜在预测因子

Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

著录项

引文网络

相似文献

相关主题

期刊订阅